{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T05:45:41Z","timestamp":1792129541098,"version":"4.4.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":120,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1053\/j.seminhematol.2026.07.002","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:46:38Z","timestamp":1785426398000},"page":"118-125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Closing the disease modification gap: Emerging therapies in myelofibrosis beyond JAK inhibition"],"prefix":"10.1053","volume":"63","author":[{"given":"Akshay","family":"Aluri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin","family":"Kishtagari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1053\/j.seminhematol.2026.07.002_bib0001","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.3390\/cancers17111834","article-title":"Current advances in the diagnosis and treatment of major myeloproliferative neoplasms","volume":"17","author":"Wang","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.seminhematol.2026.07.002_bib0002","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.3389\/fimmu.2020.02093","article-title":"Remodeling the bone marrow microenvironment: a proposal for targeting pro-inflammatory contributors in MPN","volume":"11","author":"Jutzi","year":"2020","journal-title":"Front Immunol"},{"issue":"16","key":"10.1053\/j.seminhematol.2026.07.002_bib0003","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1080\/14796694.2025.2511562","article-title":"Indirect treatment comparisons of momelotinib vs pacritinib safety and anemia outcomes in patients with myelofibrosis","volume":"21","author":"Masarova","year":"2025","journal-title":"Fut Oncol"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.07.002_bib0004","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/CCO.0000000000000898","article-title":"Novel therapeutic agents for myelofibrosis after failure or suboptimal response to JAK2 inhbitors","volume":"34","author":"Breccia","year":"2022","journal-title":"Curr Opin Oncol"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.07.002_bib0005","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1080\/14796694.2025.2461393","article-title":"Selinexor plus ruxolitinib in JAK inhibitor treatment-na\u00efve myelofibrosis: SENTRY Phase 3 study design","volume":"21","author":"Mascarenhas","year":"2025","journal-title":"Fut Oncol"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.07.002_bib0006","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1158\/1078-0432.CCR-12-0284","article-title":"Molecular pathways: JAK\/STAT pathway: mutations, inhibitors, and resistance","volume":"19","author":"Quint\u00e1s-Cardama","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.07.002_bib0007","doi-asserted-by":"crossref","first-page":"129","DOI":"10.36401\/JIPO-20-36","article-title":"JAK be nimble: reviewing the development of JAK inhibitors and JAK inhibitor combinations for special populations of patients with myelofibrosis","volume":"4","author":"Kuykendall","year":"2021","journal-title":"J Immunother Precis Oncol"},{"key":"10.1053\/j.seminhematol.2026.07.002_bib0008","article-title":"Discontinuation syndrome with JAK2 selective agents: case presentation and mechanistic insights","volume":"8","author":"Handa","year":"2024","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.07.002_bib0009","first-page":"956","article-title":"Rate of transformation to accelerated\/blast phase in patients with myelofibrosis receiving ruxolitinib: a post hoc analysis of COMFORT-I","volume":"37","author":"Mascarenhas","year":"2023","journal-title":"Leukemia"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.07.002_bib0010","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/cncr.32664","article-title":"Life after ruxolitinib: reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis","volume":"126","author":"Palandri","year":"2020","journal-title":"Cancer"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.07.002_bib0012","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"51","key":"10.1053\/j.seminhematol.2026.07.002_bib0013","doi-asserted-by":"crossref","first-page":"43137","DOI":"10.1074\/jbc.M112.413047","article-title":"Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells","volume":"287","author":"Zhang","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1053\/j.seminhematol.2026.07.002_bib0014","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1206965","article-title":"Epigenetics in myeloproliferative neoplasms","volume":"13","author":"Greenfield","year":"2023","journal-title":"Front Oncol"},{"issue":"32","key":"10.1053\/j.seminhematol.2026.07.002_bib0015","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1200\/JCO.22.01972","article-title":"MANIFEST: pelabresib in combination with ruxolitinib for Janus kinase inhibitor treatment-na\u00efve myelofibrosis","volume":"41","author":"Mascarenhas","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.07.002_bib0016","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1038\/s41591-025-03572-3","article-title":"Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial","volume":"31","author":"Rampal","year":"2025","journal-title":"Nat Med"},{"issue":"17","key":"10.1053\/j.seminhematol.2026.07.002_bib0017","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.3390\/cancers14174079","article-title":"BMS-986158, a small molecule inhibitor of the bromodomain and extraterminal domain proteins, in patients with selected advanced solid tumors: results from a phase 1\/2a trial","volume":"14","author":"Hilton","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.07.002_bib0018","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1182\/blood-2023-179428","article-title":"LIMBER-103: a phase 1 study of INCB057643, a BET inhibitor, in patients with advanced malignancies including myelofibrosis","volume":"142","author":"Watts","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.07.002_bib0019","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1182\/blood-2024-205105","article-title":"OPN-2853 (PLX2853), a BET inhibitor, in patients with myelofibrosis: interim results from the PROMise Phase I study","volume":"144","author":"Mead","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.07.002_bib0020","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/s41375-021-01464-2","article-title":"Genetic ablation of Pim1 or pharmacologic inhibition with TP-3654 ameliorates myelofibrosis in murine models","volume":"36","author":"Dutta","year":"2022","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2026.07.002_bib0021","article-title":"A phase 1\/2 study of nuvisertib (TP-3654), an investigational selective PIM1 kinase inhibitor, in combination with JAK inhibitors ruxolitinib or momelotinib in patients with myelofibrosis","volume":"144","author":"Mascarenhas","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.07.002_bib0022","unstructured":"Rein, L (2025). Clinical activity and safety of nuvisertib in patients with myelofibrosis refractory to JAK inhibitor therapy. EHA 2025 Congress, Madrid, Spain."},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2026.07.002_bib0023","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1182\/blood-2025-482","article-title":"Preliminary data from the phase I\/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed\/refractory myelofibrosis","volume":"146","author":"Mascarenhas","year":"2025","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.07.002_bib0024","doi-asserted-by":"crossref","DOI":"10.1080\/14737140.2025.2482721","article-title":"Imetelstat in myeloid malignancies: current data and future directions","volume":"25","author":"Bidikian","year":"2025","journal-title":"Expert Rev Anticanc Ther"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.07.002_bib0025","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1056\/NEJMoa1310523","article-title":"A pilot study of imetelstat in the myelofibrosis","volume":"373","author":"Tefferi","year":"2015","journal-title":"New Engl J Med"},{"issue":"26","key":"10.1053\/j.seminhematol.2026.07.002_bib0026","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1200\/JCO.20.02864","article-title":"Randomized, single-blind, multicenter phase II study of two doses of imetelstat in relapsed or refractory myelofibrosis","volume":"39","author":"Mascarenhas","year":"2021","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2026.07.002_bib0027","first-page":"7002","article-title":"Pelabresib in combination with ruxolitinib in JAK inhibitor-naive patients with myelofibrosis: results from the phase 3 MANIFEST-2 study","volume":"43","author":"Harrison","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.07.002_bib0028","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/bloodadvances.2025018706","article-title":"Selinexor plus ruxolitinib in JAK inhibitor-naive patients with myelofibrosis: a multicenter, open-label, phase 1 study","volume":"10","author":"Ali","year":"2026","journal-title":"Blood Adv"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2026.07.002_bib0029","article-title":"The efficacy and safety of selinexor in combination with ruxolitinib in ruxolitinib-treated myelofibrosis patients: the interim analysis of a prospective, open-label, multicenter, parallel-cohort, phase 2 study","volume":"142","author":"Duan","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.07.002_bib0030","article-title":"Selinexor plus ruxolitinib in JAK inhibitor-naive myelofibrosis: phase 3 SENTRY trial","author":"Bose","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2026.07.002_bib0031","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2025032360","article-title":"TRANSFORM-1 phase 3 study: efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis","author":"Pemmaraju","year":"2026","journal-title":"Blood"},{"issue":"S3","key":"10.1053\/j.seminhematol.2026.07.002_bib0032","article-title":"Selective PIM1 kinase inhibitor TP-3654 modulates pro-inflammatory cytokines and shows clinical activity in myelofibrosis: interim results from a phase 1\/2 study","volume":"7","author":"Clevenger","year":"2023","journal-title":"HemaSphere"},{"issue":"S3","key":"10.1053\/j.seminhematol.2026.07.002_bib0033","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000967752.72578.ff","article-title":"An open-label, global, phase 1b\/2 study adding navtemadlin to ruxolitinib in patients with primary or secondary myelofibrosis who have a suboptimal response to ruxolitinib","volume":"7","author":"Mascarenhas","year":"2023","journal-title":"HemaSphere"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2026.07.002_bib0034","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1182\/blood-2024-201642","article-title":"Results from the randomized, multicenter, global phase 3 BOREAS study: navtemadlin versus best available therapy in JAK inhibitor relapsed\/refractory myelofibrosis","volume":"144","author":"Mascarenhas","year":"2024","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.07.002_bib0035","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1080\/14796694.2026.2638989","article-title":"POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-na\u00efve myelofibrosis patients with a suboptimal response to ruxolitinib","volume":"22","author":"Vachhani","year":"2026","journal-title":"Fut Oncol (London, Engl)"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.07.002_bib0036","first-page":"113","article-title":"Emergence of TP53 mutations under MDM2 inhibitor therapy with idasanutlin in myelofibrosis","volume":"10","author":"Bhatt","year":"2020","journal-title":"Blood Cancer J"},{"issue":"25","key":"10.1053\/j.seminhematol.2026.07.002_bib0037","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"New Engl J Med"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.07.002_bib0038","first-page":"820","article-title":"The role of the calreticulin-MPL interaction in the pathogenesis of myeloproliferative neoplasms","volume":"135","author":"Kihara","year":"2020","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.07.002_bib0039","article-title":"Accumulation of mutated calreticulin at the cell surface drives MPL-dependent MPN progression","volume":"23","author":"Tvorogov","year":"2022","journal-title":"EMBO Rep"},{"issue":"15","key":"10.1053\/j.seminhematol.2026.07.002_bib0040","first-page":"1500","article-title":"A novel CALR-mutant-specific antibody blocks MPL signaling and provides therapeutic benefit in MPN models","volume":"143","author":"Reis","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.07.002_bib0041","series-title":"Navtemadlin versus best available therapy in patients with JAK inhibitor relapsed\/refractory myelofibrosis: primary results from the randomized phase 3 BOREAS study","author":"Mascarenhas","year":"2025"},{"key":"10.1053\/j.seminhematol.2026.07.002_bib0042","series-title":"Targeting arginase-1 mediated metabolic suppression in the myelofibrosis tumor microenvironment: preclinical and early clinical results","author":"Fultang","year":"2025"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2026.07.002_bib0043","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1182\/blood-2023-173430","article-title":"Discovery of JNJ-88549968, a novel, first-in-class CALRmutxCD3 T-cell redirecting antibody for the treatment of myeloproliferative neoplasms","volume":"142","author":"Kuchnio","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.07.002_bib0044","series-title":"Targeting the MDM2-p53 axis to overcome JAK inhibitor resistance: translational and clinical updates from the navtemadlin myelofibrosis program","author":"Pandey","year":"2025"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.07.002_bib0045","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1038\/leu.2016.233","article-title":"The CALR exon 9 mutations are mutations of high importance in the pathogenesis of the myeloproliferative neoplasms","volume":"30","author":"Holmstr\u00f6m","year":"2016","journal-title":"Leukemia"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.07.002_bib0046","first-page":"1674","article-title":"CALR mutations confer a neoantigenic epitope in myeloproliferative neoplasms","volume":"9","author":"Cimen Bozkus","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1053\/j.seminhematol.2026.07.002_bib0047","article-title":"Navtemadlin added to ruxolitinib in patients with myelofibrosis and a suboptimal response to ruxolitinib monotherapy: final results of a global phase 1b\/2 study","author":"Otoukesh","year":"2025"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.07.002_bib0048","first-page":"1150","article-title":"Clonal dynamics and clinical outcomes in patients with myeloproliferative neoplasms","volume":"143","author":"Rampotas","year":"2024","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2026.07.002_bib0050","article-title":"Navtemadlin (KRT-232) reverses the pro-fibrotic gene expression profile in myelofibrosis: correlative analysis from the BOREAS and POIESIS trials","volume":"146","author":"Rinaldi","year":"2025","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2026.07.002_bib0051","article-title":"Hematological and clinical improvements with elritercept (KER-050, TAK-226) at the recommended phase 2 dose (RP2D) in patients with myelofibrosis (MF) receiving ruxolitinib: updated results from the phase 2 RESTORE trial","volume":"146","author":"Rinaldi","year":"2025","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.07.002_bib0052","unstructured":"BM Squibb. (2025). Bristol Myers Squibb announces topline results from phase 3 INDEPENDENCE trial for reblozyl (luspatercept-aamt) in adult patients with myelofibrosis-associated anemia. https:\/\/news.bms.com\/news\/details\/2025\/Bristol-Myers-Squibb-Announces-Topline-Results-from-Phase-3-INDEPENDENCE-Trial-for-Reblozyl-luspatercept-aamt-in-Adult-Patients-with-Myelofibrosis-associated-Anemia\/default.aspx, Accessed June 21, 2026."},{"issue":"3","key":"10.1053\/j.seminhematol.2026.07.002_bib0053","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000054","article-title":"LSD1 Inhibition prolongs survival in mouse models of MPN by selectively targeting the disease clone","volume":"2","author":"Jutzi","year":"2018","journal-title":"HemaSphere"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.07.002_bib0054","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1038\/s41375-025-02594-7","article-title":"Ruxolitinib mediated paradoxical JAK2 hyperphosphorylation is due to the protection of activation loop tyrosines from phosphatases","volume":"39","author":"Gorantla","year":"2025","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2026.07.002_bib0055","article-title":"AJ1-11095, a potent and highly selective type-II JAK2 inhibitor, shows enhanced therapeutic efficacy as compared with type-I JAK2 inhibitor ruxolitinib in models of myeloproliferative neoplasms (MPNs)","volume":"146","author":"Usart","year":"2025","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2026.07.002_bib0056","article-title":"A multicenter, open-label phase 1 study of INCB160058, a first-in-class JAK2V617F mutant\u2013selective inhibitor, in patients with myelofibrosis, polycythemia vera, or essential thrombocythemia","volume":"146","author":"Gotlib","year":"2025","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.07.002_bib0057","doi-asserted-by":"crossref","first-page":"12085","DOI":"10.1021\/acs.jmedchem.5c00950","article-title":"Discovery of a proteolysis-targeting chimera degrader of JAK2 as a potential therapeutic agent for JAK2-mediated myeloproliferative neoplasms","volume":"68","author":"Wang","year":"2025","journal-title":"J Med Chem"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196326000831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196326000831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:57:56Z","timestamp":1792126676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196326000831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0037196326000831"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.07.002","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Closing the disease modification gap: Emerging therapies in myelofibrosis beyond JAK inhibition","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}